CLINICAL TRIALS PROFILE FOR PREVACID IV

All Clinical Trials for PREVACID IV

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00204373 ↗	Treatment of Zollinger-Ellison Syndrome With Prevacid	Completed	Takeda Pharmaceuticals North America, Inc.	Phase 4	2003-03-01	The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.
NCT00204373 ↗	Treatment of Zollinger-Ellison Syndrome With Prevacid	Completed	Charles Mel Wilcox, MD	Phase 4	2003-03-01	The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.
NCT00211614 ↗	Proton Pump Inhibitor Therapy for Mild to Moderate Obstructive Sleep Apnea	Withdrawn	MetroHealth Medical Center	N/A	2006-07-01	Obstructive Sleep Apnea (OSA) is common in modern society, affecting up to 5% of working middle-aged adults in the United States. Obesity is the number one risk factor for the development of OSA. Consequences of untreated OSA are varied and significant and included numerous neuropsychiatric parameters such as mood alterations, depression, anxiety, diminished social interactions, and decreased quality of life. Mounting evidence suggests that treatment of OSA can improve many of these outcomes. The primary treatment modality for this condition is continuous positive airway pressure (CPAP). This device delivers positive pressure to the upper airway in order to prevent its collapse during sleep. Unfortunately, many patients do not choose to use CPAP or have difficulty with these devices. This results in many individuals with OSA either going without therapy or unable to reap the full benefits of treatment. Gastroesophageal reflux (GERD) is also common in the United States and may, in some instances, be directly related to weight gain. Survey studies have suggested that symptomatic GERD is more common in patients with OSA. Whether there exists a cause and effect relationship between these two conditions is not known at present. It has been suggested that GERD may contribute to OSA by narrowing the upper airway. This study will examine the effect of treatment of GERD on mild to moderate OSA. Fifty individuals identified as having mild to moderate OSA (diagnosed by overnight sleep study or PSG) and GERD (confirmed by an esophageal probe) will be enrolled. Both men and women will be included in this study and no "special populations" will be utilized. Subjects will fill out questionnaires to subjectively measure sleepiness, OSA-related symptoms, GERD-related symptoms, and sleep apnea-related quality of life. They will then be randomized to receive either 12 weeks of the proton pump inhibitor lansoprazole (Prevacid) or placebo (twenty five subjects per group). Upon completion of the 12 week trial, subjects will return and the following data will be collected; repeat all of the baseline questionnaires, repeat PSG and repeat pH probe. Results from this study will help to establish the relative effectiveness of a novel form of therapy for a common yet difficult to manage medical condition. . The risks to subjects enrolled in the study are minimal and therefore the benefit to risk ratio is heavily in favor of performing the study.
NCT00215787 ↗	Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease	Completed	Head and Neck Surgery Associates	N/A	2005-09-01	Although nasal polyposis has been recognized as an inflammatory process for many years, the true etiology of nasal polyposis mainly unknown. Despite surgical removal, the recurrence rate after surgery has been reported as high as 87% within the first year after surgery. Anecdotally the Principal Investigator found an incidence of pH probe-proven laryngopharyngeal reflux approaching 80% in his patients with nasal polyposis. Although his number of cases was small, the incidence of recurrence of polyps in these patients was 17%. The PI believes that such an association is too great to be explained by chance alone, and deserves further study. He anticipates two contributions to the literature from this study, the first documenting the incidence of extraesophageal (laryngopharyngeal) reflux in patients with polyposis, and the second showing the impact of reflux treatment on the recurrence rate of the polyps, initially after one year of therapy.

Clinical Trial Conditions for PREVACID IV

Condition Name

Condition Name for PREVACID IV
Intervention	Trials
Healthy	9
Gastroesophageal Reflux	6
Erosive Esophagitis	4
Asthma	3

Condition MeSH

Condition MeSH for PREVACID IV
Intervention	Trials
Gastroesophageal Reflux	14
Esophagitis	6
Laryngopharyngeal Reflux	3
Ulcer	3

Clinical Trial Locations for PREVACID IV

Trials by Country

Trials by Country for PREVACID IV
Location	Trials
United States	123
China	68
Korea, Republic of	16
Malaysia	12
Canada	10

Trials by US State

Trials by US State for PREVACID IV
Location	Trials
California	7
Missouri	7
Florida	6
Georgia	5
Ohio	5

Clinical Trial Progress for PREVACID IV

Clinical Trial Phase

Clinical Trial Phase for PREVACID IV
Clinical Trial Phase	Trials
Phase 4	18
Phase 3	8
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for PREVACID IV
Clinical Trial Phase	Trials
Completed	33
Terminated	5
Withdrawn	2

Clinical Trial Sponsors for PREVACID IV

Sponsor Name

Sponsor Name for PREVACID IV
Sponsor	Trials
Takeda	8
TAP Pharmaceutical Products Inc.	6
AstraZeneca	6

Sponsor Type

Sponsor Type for PREVACID IV
Sponsor	Trials
Other	42
Industry	31
NIH	2

PREVACID IV: Clinical Trial Status, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

PREVACID IV (lansoprazole for injection) is a proton pump inhibitor (PPI) used for the short-term treatment of upper gastrointestinal bleeding in hospitalized patients. Its efficacy and safety profile are critical for its positioning within the acute care setting. This analysis details the current clinical trial landscape, market performance, and future projections for PREVACID IV.

What is the current regulatory status and clinical trial pipeline for PREVACID IV?

PREVACID IV is approved by the U.S. Food and Drug Administration (FDA) for intravenous administration in hospitalized patients with specific conditions. The primary indication focuses on its use as a continuous intravenous infusion for the treatment of gastrointestinal bleeding, particularly related to peptic ulcer disease.

The approved indication for PREVACID IV (lansoprazole for injection) is for the treatment of patients with a history of gastrointestinal bleeding, and for whom continuous intravenous infusion of a proton pump inhibitor is indicated, as a bridge therapy to initiating oral lansoprazole [1]. This includes the prevention of rebleeding.

As of the latest available data, there are no ongoing Phase III or Phase IV clinical trials listed for PREVACID IV as a new investigational drug or for expanded indications by Takeda Pharmaceuticals, the original developer. The current focus is on its established use within the approved indication. Post-market surveillance and any necessary safety updates would be handled through standard regulatory reporting mechanisms.

The drug's development history primarily involved establishing its pharmacokinetic and pharmacodynamic profile, demonstrating bioequivalence to oral formulations in specific patient populations, and confirming its efficacy and safety in acute settings. Studies have focused on dose-ranging, infusion rates, and comparative effectiveness against other acid suppression therapies in patients with gastrointestinal bleeding [2].

Key clinical considerations for PREVACID IV include its rapid onset of action, which is crucial for managing acute bleeding events. Studies have evaluated its role in significantly reducing gastric acid secretion, creating a more favorable environment for ulcer healing and clot stabilization [3].

How does PREVACID IV perform in the current market?

The market for intravenous PPIs is characterized by established players and a consistent demand in hospital settings, particularly in intensive care units (ICUs) and for patients undergoing procedures or experiencing acute gastrointestinal events. PREVACID IV occupies a specific niche within this market.

PREVACID IV's market performance is directly tied to its indication for acute gastrointestinal bleeding. This segment of the PPI market is influenced by hospital admission rates, the prevalence of peptic ulcer disease, and the adoption of guidelines for acid suppression therapy in critically ill patients.

Competitors in the intravenous PPI market include other lansoprazole formulations, pantoprazole for injection (Protonix IV), and esomeprazole for injection (Nexium IV). These agents offer similar mechanisms of action and are often used interchangeably depending on formulary status, physician preference, and formulary cost considerations.

Market Share and Sales Data: Specific, granular sales data for PREVACID IV as a standalone product is not readily available in the public domain, as it is often reported within broader lansoprazole or PPI categories by market research firms. However, analysis of the intravenous PPI market indicates a stable demand driven by its critical care applications.

• Estimated Market Share: While precise figures fluctuate, intravenous lansoprazole formulations, including PREVACID IV, generally hold a segment of the intravenous PPI market. This segment is estimated to be a smaller portion of the overall PPI market, which is dominated by oral formulations.
• Competitive Landscape: Protonix IV and Nexium IV are significant competitors. Their market presence is often influenced by physician prescribing habits, hospital contracts, and the availability of generic options.
• Pricing: Pricing for intravenous PPIs is typically higher than oral formulations due to the complexity of manufacturing sterile injectable products and the specialized administration required. The price of PREVACID IV will be competitive within this tier, subject to negotiations with hospital systems and group purchasing organizations.

Factors Influencing Market Demand:

• Hospital Protocols: Adoption of evidence-based guidelines for managing gastrointestinal bleeding and stress ulcer prophylaxis in ICU patients directly impacts demand for intravenous PPIs.
• Cost-Effectiveness: While efficacy is paramount in acute care, the cost of intravenous formulations relative to oral options and other therapeutic interventions plays a role in formulary decisions.
• Availability of Alternatives: The presence of multiple intravenous PPI options allows for competition, potentially impacting pricing and market share.

The market for PREVACID IV is mature, with demand primarily driven by its established clinical utility in specific inpatient scenarios. Growth opportunities are limited by its focused indication and the competitive landscape of intravenous acid suppressants.

What are the projected market trends and future outlook for PREVACID IV?

The future outlook for PREVACID IV is intrinsically linked to the broader trends in gastrointestinal disease management, hospital care, and the pharmaceutical market for acid suppressants. Given its established role and mature product status, significant growth is unlikely, but its continued utility is anticipated.

Projected Market Trends:

1. Stable Demand in Acute Care: The need for effective acid suppression in hospitalized patients with gastrointestinal bleeding or those at high risk for stress ulcers is expected to remain consistent. PREVACID IV will continue to be utilized in this setting, especially where continuous intravenous infusion is deemed necessary.
2. Competition from Established and Emerging Therapies: The intravenous PPI market is competitive. Pantoprazole and esomeprazole injections remain strong contenders. Any new advancements in GI bleeding management or novel acid suppression mechanisms could potentially impact the market share of existing therapies, though rapid displacement is not anticipated for established agents like PREVACID IV.
3. Cost Pressures in Healthcare: Hospitals and healthcare systems are under continuous pressure to manage costs. This may lead to increased emphasis on cost-effective formulary choices. The pricing and availability of generic intravenous PPIs, if applicable, or the comparative pricing of branded agents, will influence prescribing patterns.
4. Evolving Clinical Guidelines: Updates to guidelines from gastroenterological and critical care societies regarding the management of GI bleeding and stress ulcer prophylaxis could shift treatment paradigms. However, PPIs are deeply entrenched in these guidelines.
5. Focus on Oral Transition: A key aspect of managing patients treated with intravenous PPIs is the timely transition to oral therapy once clinically indicated. The effectiveness and ease of switching from PREVACID IV to oral lansoprazole are important factors in its overall utility and cost-effectiveness within a patient's treatment course.

Future Outlook:

PREVACID IV is expected to maintain its position as a valuable therapeutic option for its approved indication in the short-to-medium term. Its future is characterized by:

• Sustained but Modest Usage: Demand will likely remain steady, driven by its established role in specific inpatient care scenarios, particularly in the management of acute GI bleeds.
• Limited Expansion Potential: Without new clinical trial data supporting expanded indications or significant improvements over existing therapies, substantial market expansion is improbable.
• Price Sensitivity: As a mature product, PREVACID IV's market performance will be sensitive to pricing strategies and competitive offers from other intravenous PPIs.
• Impact of Generic Competition: The availability and pricing of generic intravenous PPIs could influence market dynamics, although the complexity of sterile injectables can sometimes limit broad generic penetration compared to oral forms.

The overall outlook suggests that PREVACID IV will continue to serve a critical, albeit niche, role in acute care settings. Its longevity will depend on its continued efficacy, safety, and competitive positioning against other intravenous acid suppressants.

Key Takeaways

• PREVACID IV is approved by the FDA for short-term intravenous use in hospitalized patients with gastrointestinal bleeding, serving as a bridge to oral therapy.
• There are no ongoing Phase III or IV clinical trials for PREVACID IV to support new indications or significant product development.
• The intravenous PPI market is competitive, with key rivals including pantoprazole and esomeprazole injections.
• PREVACID IV's market performance is stable, driven by its established role in acute care settings like ICUs, but growth is limited by its mature product status and focused indication.
• Future market trends indicate sustained but modest usage, with ongoing competition and cost pressures influencing its positioning.

Frequently Asked Questions

1. What specific conditions does PREVACID IV treat in hospitalized patients?

PREVACID IV is indicated for the treatment of patients with a history of gastrointestinal bleeding and for whom continuous intravenous infusion of a proton pump inhibitor is indicated, as a bridge therapy to initiating oral lansoprazole. This includes the prevention of rebleeding [1].

2. Are there any ongoing clinical trials for PREVACID IV to expand its uses?

As of current public records, there are no ongoing Phase III or IV clinical trials for PREVACID IV investigating new indications or significant product enhancements by Takeda Pharmaceuticals. Its current development appears focused on its established use [1].

3. How does PREVACID IV compare in terms of market share to other intravenous proton pump inhibitors like Protonix IV or Nexium IV?

While precise, disaggregated sales figures for PREVACID IV are not publicly disclosed, it competes within a mature intravenous PPI market. Protonix IV and Nexium IV are also significant players, and market share among these agents is influenced by hospital formulary decisions, physician preference, and competitive pricing [2].

4. What are the primary drivers of demand for PREVACID IV in the market?

Demand for PREVACID IV is primarily driven by its use in managing acute gastrointestinal bleeding in hospitalized patients and its role in preventing rebleeding. Hospital admission rates for these conditions and the adoption of established clinical guidelines for acid suppression in critical care settings are key factors [3].

5. What is the projected impact of generic competition on PREVACID IV?

The impact of generic competition on PREVACID IV will depend on the availability and pricing of generic intravenous lansoprazole. While generic entry typically increases price pressure, the manufacturing complexity of sterile injectable products can sometimes moderate the pace and extent of generic market penetration compared to oral medications.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from [Specific drug approval information may require searching FDA's database directly for lansoprazole for injection].

[2] Market Research Reports on the Global Proton Pump Inhibitor Market (Various Publishers). (2023-2024). Analysis of competitive landscape and market share within the PPI segment, including intravenous formulations.

[3] Clinical studies on lansoprazole for intravenous administration and management of gastrointestinal bleeding. (Data available through scientific literature databases such as PubMed, clinicaltrials.gov).